Galena Biopharma and Dr. Reddy's Laboratories Ltd. have entered a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax is the immunodominant nonapeptide derived from the HER2 protein, a target for therapeutic intervention in breast cancer. Based on a successful Phase II trial, which achieved its primary endpoint of disease-free survival, the FDA granted NeuVax a Special Protocol Assessment (SPA) for a Phase III study.
"This partnership with Dr. Reddy's is consistent with our strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy," said Mark J. Ahn, Ph.D., president and chief executive officer of Galena Biopharma. "The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population, if approved."
G V Prasad, chairman and chief executive officer, Dr. Reddy's, said, "The partnership accelerates our strong commitment to innovation and efforts to bring newer options for cancer patients. We are delighted with our partnership with Galena Biopharma and we believe NeuVax can be a good potential treatment option to prevent the recurrence of breast and gastric cancer."
Galena, Dr. Reddy's Enter Strategic NeuVax Pact
By Kristin Brooks
Published January 14, 2014
blog comments powered by Disqus